LONDONThe chief executive of insulin maker Novo Nordisk AS said he has no plans to pursue any big acquisitions suggesting his company will be sitting out the frenzy of dealmaking that has convulsed the global pharmaceutical industry this year Denmarkbased Novo Nordisk is controlled by a foundation that makes it all but impossible for it to be acquired by another company But it is among a handful of pharmaceutical companies large enough to be on the hunt for acquisitions itself In the recent past Novo Nordisk executives
  